Troutman Sanders Adds Five New IP Attorneys, Creates Life Sciences Practice Team
Troutman Sanders LLP is pleased to announce the addition of seven intellectual property lawyers who have joined the firm’s newly created Life Sciences practice team.
The new attorneys in the firm's New York office are Albert L. Jacobs Jr., Gerard F. Diebner, Daniel A. Ladow, Magnus Essunger and Timothy M. Salmon. Prior to joining Troutman Sanders, the five worked most recently for the boutique IP law firm of Albert Jacobs LLP in New York, where Jacobs was chairman and managing partner.
The new attorneys in New York and Chicago will form the bulk of the firm’s new Life Sciences practice team, which will assist a broad range of clients within the life sciences and associated technology industry from embryonic beginning and development issues onward through clinical drug testing and regulatory approval to sales and marketing issues. Members also will provide clients legal assistance in corporate, finance, the full range of intellectual property services, including prosecution, opinions, federal court litigation, Hatch Waxman litigation, the ITC, CAFC appeals, as well as patent interferences, client counseling on patent portfolios, and due diligence. The team will also provide INN creation and approval, clinical development, federal regulatory pre- and post-approval, compliance, commercialization and risk management issues (including litigation).
"Coupling these five lawyers with Diane and Rob in Chicago gives Troutman Sanders the critical mass needed to launch a Life Sciences practice team," said Doug Salyers, head of Troutman Sanders’ IP practice group. "This new team will greatly enhance the services we can provide to our many clients in this industry segment."
The new attorneys have extensive experience not only in Life Science, but in a broad range of technologies, including chemical and business methods.
